Prophylaxis of acute graft versus host disease in allogenic hematopoietic stem cell transplantation
WANG Zhi-ming
WANG Lin
CHEN Xiao-xia
LUO Xian-sheng
HE Li-li
XU Dan-dan
LI Xing
FU Rong-xiang
WANG Yun-ying
LI Li-qiong
HUANG Zi-ying
TAN Lian
Abstract：Objective To study the prophylaxis of acute graft versus host disease in hematopoietic malignancy patients with allogenic hematopoietic stem cell transplantation. Methods In 15 cases of allogenic hematopoietic stem cell transplantation, we adopted prophylaxis include recombinant human granulocyte colony stimulating factor(rhG-CSF) to mobilize donor stem cell, cyclosporine A (GSA) infusion and mycophenolate mofetil (MMF) oral from -7 d( "-" means befor infusion of donor stem cell, "+" means after infusion of donor stem cell), cyclophosphamide (CTX) infusion during - 5- - 4 d, anti-thymocyte globulin (ATG) infusion during - 5 d- - 2 d, interleukin 11(IL-11 ) subcutaneous injection during -2 d- + 10 d, methotrexate(MTX) infusion at +1 d, +3 d, +6 d and + 11 d to prevent aGVHD. Results All 15 cases achieved complete implantation. The incidence of aGVHD Ⅱ～Ⅳ degree was 20%. The incidence of aGVHD Ⅲ-Ⅳ degree was 6.7%. Median follow-up time was 30. 7(4-65)months. There was no relapse. All patients were hematopoietic malignancy free survival. Conclusion It is an effective prophylaxis and worth of spreading to prevent GVHD in hematopoietic malignancy patients with allogenic hematopoietic stem cell transplantation that combined uses rhG-CSF, GSA, MMF, CTX, ATG, IL-11, and shortterm MTX.
Keywords：Hematologic diseasesStem cell transplantationGraft versus host reaction
Publication Date：2010-01-01
Online Publishing Date：2026-09-14(First online date of this platform, not the publication date of the document)